Regeneron is planning to re-apply to the FDA with a new pre-filled syringe manufacturing filler in January 2026.

Polpharma Biologics today announced Ranivisio® PFS (ranibizumab biosimilar pre-filled syringe), is now commercially available in France. Ranivisio® is the first Lucentis® biosimilar which is offered ...

Groninger FlexPro 50 Isolator Line provides U.S.-based fill/finish capacity for partners in oncology and specialty drug manufacturing.

Discover why Regeneron Pharmaceuticals, Inc.'s Q3 earnings impress, fueled by Dupixent growth and a robust pipeline. Click ...

Despite the rejection, analysts saw Regeneron’s use of an alternate filler for Eylea HD as a positive development, with BMO Capital Markets noting that this could signal the end of manufacturing ...

Third quarter 2025 revenues increased 1% to $3.75 billion versus third quarter 2024Dupixent® global net sales (recorded by Sanofi) increased 27% to $4.86 billion EYLEA HD® U.S. net sales increased 10% ...

Alvotech and Advanz Pharma Receive Marketing Authorizations for Gobivaz, a Biosimilar to Simponi (golimumab), from the MHRA.

Alvotech and Advanz Pharma have announced the receipt of marketing authorisations from the UK Medicines and Healthcare products Regulatory Agency (MHRA) for all four formulations of Gobivaz - Alvotech ...

Regeneron Pharmaceuticals, Inc. REGN reported third-quarter 2025 adjusted earnings per share (EPS) of $11.83, which ...

Milestone expands India's role in global biologics manufacturing; collaboration with Cipla underscores commitment to quality and reliability Kemwell Biopharma Pvt Ltd ("Kemwell"), a leading global ...

While investment has slowed in radiopharmaceuticals, analysts predict increased interest to come as Novartis shows just how successful radiopharmaceuticals can be.

Health Biotech Limited (Health Biotech), a research and development-driven pharmaceutical company from India, successfully ...